- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Monkeypox is a viral disease caused by the monkeypox virus, belonging to a family of rabies viruses known as the orthopoxvirus family, first identified in laboratory monkeys in 1958, with the first human cases reported in the Democratic Republic of Congo in 1970. Occurs mainly in central and western Africa.
Monkeypox rash begins often with fever, headache, muscle pain, and swollen muscles. This is followed by a rash that usually starts on the face and spreads to other parts of the body, such as the arms and legs. The rash progresses in several stages, including macules, papules, vesicles, pustules, and scabs. The disease is zoonotic, which means it can be transmitted from animals to humans primarily through respiratory transmission of blood, body fluids, or skin lesions from infected animals such as rodents and primates of condensation, contact with contaminated materials
Preventive measures include avoiding contact with potentially infected animals, practicing good hygiene, and using protective equipment at health care facilities There is no specific treatment, however, supportive care and diagnostic therapies can help manage the disease. The smallpox vaccine has been shown to provide some protection against monkeypox, and vaccination campaigns in outbreak situations have been used to prevent the spread of the virus.
The monkeypox marketplace, encompassing diagnostics, vaccines, and therapeutics, has gained enormous interest because of the recent international outbreaks of the virus. Monkeypox, a zoonotic virus associated with smallpox, has led to accelerated efforts in surveillance, prevention, and remedy, mainly in areas where the virus has re-emerged. The market is pushed with the aid of the pressing want for effective diagnostics, the development of vaccines, and the availability of antiviral remedies to govern and prevent the unfolding of the virus.
Key growth drivers encompass heightened international cognizance and the urgency to develop fast diagnostic exams and vaccines in response to outbreaks. Additionally, the re-emergence of monkeypox in non-endemic areas has spurred studies and development in antiviral treatment plans and public health projects aimed toward containing the virus.
Challenges in the market consist of the confined availability of specific remedies and vaccines, the logistical problems in dispensing those in affected areas, and the want for global collaboration to control outbreaks. Despite those demanding situations, the point of interest on preparedness and fast response to infectious diseases is predicted to be the pressure endured boom and innovation in the monkeypox market.
The monkeypox market including vaccines, treatments, and diagnostics is driven primarily by North America and Europe with major contributions from the United States and Western Europe. Growing awareness of monkeypox as a disease re-emergence of infectious agents, the need for effective vaccination and treatment, and ongoing efforts to monitor and prevent infection. The costs and market growth support growth in vaccination, antimicrobial therapy, and diagnostic technologies aimed at improving the diagnosis and management of monkey disease Increased global focus on disease transmission infection preparation, and response especially after recent outbreak also helps towards market growth.
Untapped opportunities are evident in Asia-Pacific and other emerging markets, where increased surveillance, vaccination, and treatment capabilities are needed to prevent potential pandemic outbreaks These areas can grow as investments in public health systems, expanding research and development efforts in vaccines and treatments Advances in Cost treatment technologies, In new ways to control epidemics role, innovations such as the development of sensitive and affordable diagnostics and the establishment of global health partnerships can further stimulate market growth and make monkey control efforts well.
| Sl No | Company | Product Description | Analyst View |
| 1. | Bavarian Nordic | JYNNEOS (MVA-BN) Vaccine FDA-approved, non-replicating vaccine, dual indication for smallpox and monkeypox. | Bavarian Nordicâs JYNNEOS vaccine is a leader in the prevention of monkeypox diseases, mainly due to its FDA approval and safety profile. The lack of replication of vaccines makes them suitable for several populations, including immunocompromised individuals, which are important in controlling the infection. Two cases of acne and diarrhea add considerable scope, enabling public health programs to make greater use of it. The global rise in monkeypox has accelerated demand, positioning JYNNEOS as an important tool in global vaccination campaigns. |
| 2. | SIGA Technologies | TPOXX (Tecovirimat) Oral antiviral, FDA-approved for smallpox, expanded use for monkeypox under EUA. | TPOXX has received considerable attention as an antimicrobial for the treatment of monkeypox, primarily because of its expanded use under an Emergency Use Authorization (EUA). Originally developed for tuberculosis, TPOXX's ability to fight orthopoxviruses, including monkey tuberculosis, provides an important treatment when vaccines are not widely available, making it easier to distribute and administer in outbreak areas. As monkey disease continues to spread, the role of TPOXX in managing acute events and reducing infection is likely to expand. |
| 3. | Qiagen | QIAstat-Dx Respiratory SARS-CoV-2/MPXV Panel Multiplex PCR panel, detects SARS-CoV-2 and monkeypox virus in a single test. | Qiagenâs launch of the QIAstat-Dx panel reflects the growing need for integrated diagnostic solutions that can detect multiple pathogens simultaneously. The ability of the commission to test for SARS-CoV-2 and monkeypox in a single test is particularly useful in the current context, where co-infection and differentiation are major concerns. This is instrumental in prevention. |
| 4. | Roche Diagnostics | cobas® MPX for monkeypox virus detection High-throughput PCR system, specific to monkeypox, CE-IVD marked. | Roche's cobas® MPX assay is a revolution in the diagnostic method, which enables better detection and specificity of the monkey virus The CE-IVD marking facilitates its use in European laboratories species, and meets the urgent need for reliable testing in the current epidemic outbreak. The high throughput capability of this product is particularly important in meeting the needs of large-scale investigations, ensuring timely discovery and isolation of data to limit Rocheâs focus on the expansion of its research portfolio to include emerging infectious diseases further expansion positions the company as a key player in internal global health. |
The monkeypox market is characterized by a focus on exploration, treatment, and vaccination aimed at controlling and preventing outbreaks of this pathogen Key players in this market and pharmaceutical companies, biotechnology institutes, and research institutes actively involved in the development and marketing of monkey products as vaccines), SIGA Technologies (known for its anti-tuberculosis, TPOXX, reused for monkeypox), and public health organizations such as the CDC and WHO, which play an important role in the management and response to outbreaks.
Periodic outbreaks of monkeys have driven the market, necessitating the need for effective diagnostic tools, vaccinations, and treatment Recent outbreaks have brought into focus greater reliance on early diagnosis, antibiotics, and prophylaxis. Emphasis has also been placed on improving vaccination coverage and accessibility, especially in areas at high risk of outbreaks. The competitive landscape includes not only innovation but also rapidly scaling up production to meet emerging needs is critical for governments, public health agencies, and the private sector to collaborate on the methodology essential to expedite research, ensure the availability of resources, and address public health concerns related to monkeypox.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Average B2B price |
| 8 | Regional Analysis and Trends |
| 9 | Impact of Public Health Policies on Monkeypox Demand |
| 10 | Technology trends in the Industry |
| 11 | Major key driver in the market |
| 12 | Recent product development in the market |
| 13 | Manufacturing footprint for major players |
| 14 | Recent Orders and Supply Chain Developments in Global Monkeypox Market |
| 15 | Market dynamics and strategic initiatives |
| 16 | Analysis of Monkeypox Initiatives on Market Growth |
| 17 | Impact of Sustainable Practices on Market trends |
| 18 | Market Size, Dynamics, and Forecast by Geography, 2024-2030 |
| 19 | Market Size, Dynamics, and Forecast by End User, 2024-2030 |
| 20 | Market Size, Dynamics and Forecast by Technology, 2024-2030 |
| 21 | Market Size, Dynamics, and Forecast by Application, 2024-2030 |
| 22 | Pricing Strategies and Market Positioning |
| 23 | Competitive Landscape |
| 24 | M&A in past 12 months |
| 25 | Growth strategy of leading players |
| 26 | Market share of vendors, 2023 |
| 27 | Company Profiles |
| 28 | Unmet needs and opportunity for new suppliers |
| 29 | Conclusion |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.